Determine Phase Appropriate Activities A Lifecycle Approach for Analytical Procedures and Methods Validation
|
|
- Elmer Henderson
- 6 years ago
- Views:
Transcription
1 Determine Phase Appropriate Activities A Lifecycle Approach for Analytical Procedures and Methods Validation Xiande (Andy) Wang, Ph.D. Analytical Development Janssen Pharmaceutical Companies of Johnson & Johnson IVT Analytical Procedures and Validation, December 2015, Philadelphia
2 Outline I. Life Cycle of Analytical Methods II. Method Development/Validation at Early Stage (IND) III. Method Development/Validation at Late Stage (NDA) a. Notes on FDA Guideline b. Systematic method development c. Case studies of robust method development IV. Analytical methods for post-marketing support VII. Summary
3 Full Life Cycle of Pharmaceutical Products Supply Chain/ Operations CMC/R&D
4 Full Life Cycle of Pharmaceutical Products NME NEW SYNTHESIS/ FORMULATION Supply Chain/ Operations STABILITY MONITORING IND CMC/R&D NDA TECH TRANSFER LAUNCH
5 Phase Appropriate Activities NME: Identification; isolation; purity profile IND: Method development/validation (abbreviated) NDA: Method development/validation (thorough) LAUNCH: Primary method transfer; stability studies TECH TRANSFER: Secondary method transfer STABILIY MONITORING: Continuous stability studies Method re-evaluation Gap assessment (methods, validation, specifications) Method gap validation/re-development/re-validation New Synthesis/formulation Method development/validation/approval/transfer
6 IND
7 Method Development to Support Early Formulation Development The chemistry, manufacturing and controls (CMC) aspect of drug development is focused on producing medicines suitable for human use with specified quality, safety and efficacy characteristics The drug development program is geared towards thorough understanding of the drug product s performance identification of drug product s critical characteristics demonstration of drug s safety and efficacy ultimately leads to the review and approval of the drug Formulation development Proper API characterization (particle size, polymorph, bulk density) Solubility (intrinsic, ph dependent, saturation) Hygroscopicity study Impurity profile Drug excipient compatibility studies Probe stability studies
8 Validation at IND Vs. NDA IND NDA
9 Method Development to Support Late Formulation Development Support the following studies: Use of overages Use of excipients, approved colors Adequate optimization study data on process controls Dissolution profile Stability studies Adequate batch size and number of batches Chamber temperature and humidity condition appropriate to the target market Adequate data at the time of submission Photo stability study Proper container orientation (specially for liquid products) Adequate stability study on bulk shipment pack (if intended to ship it for repackaging) Adequate parameters covered under stability protocol (e.g.: microbial testing)
10 Method Development in Formulation Development: Building-in Quality through Adequate Analytical Testing/Methods Meeting Pharmacopoeial requirement / ICH guidelines Second identification test Adequate impurities & residual solvent specification Testing for preservatives, anti-oxidants wherever used Test for breakability / content uniformity Test for establishing polymorphic conversions Test for water content in solid dosage form Analytical methods: Validated (e.g.: LOD, LOQ in RS method) Stability indicating (for stability studies) Forced degradation studies performed Method development report (adequate justification for choice / selection of method and conditions)
11
12 Notes on New Guidance Supersedes 2000 draft guidance on Analytical Procedures and Methods Validation Will replace 1987 FDA guidance for industry on Submitting Samples and Analytical Data for Methods Validation Applies to DS and DP in NDA, ANDA, BLA and DMF. Not address: IND biological and immunochemical assays revalidation of existing analytical methods
13 Notes on New Guidance: Method Robustness during Method Development During method development, parameters may be evaluated: specificity, linearity, LOD, LOQ, range, accuracy and precision. During early stage of method development, method robustness should be evaluated. Development data should be submitted if they support method validation. A systematic approach (e.g. DOE) should be used for method robustness evaluation.
14 Notes on New Guidance: Details on Chemicals/Materials
15 Notes on New Guidance: Combination of Challenges to Demonstrate Specificity
16 Notes on New Guidance: Notification to FDA; Robustness Data Required
17 Notes on New Guidance: Compendial Methods
18 Notes on New Guidance: Statistical Analysis and Models
19 Notes on New Guidance: Life Cycle Management of Methods
20 Notes on New Guidance: Changes to Methods
21 Notes on New Guidance: Revalidation
22 Notes on New Guidance: Method Comparability Study (1)
23 Notes on New Guidance: Method Comparability Study (2)
24 Notes on New Guidance: Method Comparability Study (3)
25 Notes on New Guidance: Method Transfer
26 Notes on New Guidance: Report Post-marketing Changes
27 Analytical Techniques/Methods Titration HPLC GC CE AAS Loss on Drying Karl-Fisher UV-VIS Sulfate ash Heavy metals Insoluble matter Color and clarity Dissolution Appearance IR DSC Optical rotation Melting point/melting profile NMR MS
28 Stability-indicating Method A stability-indicating assay is a validated quantitative analytical procedure that can detect the changes with time in the pertinent properties of the drug substance and drug product. A stability-indicating assay accurately measures the active ingredients, without interference from degradation products, process impurities, excipients, or other potential impurities Key characteristics of a stability-indicting method: Accuracy Precision Sensitivity (LOD/LOQ) Specificity Peak purity Mass balance Resolution Forced degradation Orthogonal method
29 Systematic Method Development Process Samples are stressed under different conditions Stressed samples are analyzed with a generic method Representative stressed samples are chosen Process impurities and/or excipients are obtained The methods are optimized A primary method and an orthogonal secondary method are identified Method screening is conducted with selected samples Stressed samples are analyzed with optimized methods The primary method is ready for further optimization / validation
30 Stressing of API Purposes: To facilitate method development/validation To aid in development of the first API specification To understand the degradation pathways of the API to facilitate rational product development To screen for possible formation of potential genotoxins Provides a control baseline for excipient compatibility studies Target 5-15% degradation with secondary degradation minimized Typical conditions for API might be: Solid under light or heat/humidity In acid, base or buffered media of ph 1-10 with peroxide (and/or free radical initiator) With water under light or heat
31 Stressing of Formulations Purposes: To facilitate method development/validation Pre-formulation investigations To confirm the mass balance Solid state degradation and stability assessment Role of excipients in API instability Typical conditions might be: Solid under light or heat/humidity In acid, base or buffered media of ph 1-10 with peroxide (and/or free radical initiator) With water under light or heat Different grade/source of excipients
32 A Generic HPLC Method Column: Endcapped C18, 15x0.46cm, 3.5um (or 1.7 um) Mobile phase A: 0.05%TFA in H 2 O Mobile phase B: 0.05% TFA in MeCN 10/90, A/B Flow rate: 1.2mL/min 20min Run time: 25 min 90/10,A/B 5min Ref: X Wang, Generic HPLC Methods for Pharmaceuticals, Nov 14, 2006, EAS, Somerset, New Jersey. 32
33 Representative Stressed Samples Deploy the right technique LC-MS or LC/MS/MS Establish the appropriate threshold 0.01% or 0.03% Preparation of degradants Purchase Preparative separation Organic synthesis 33
34 HPLC Column Screen Set: An Example Orthogonal Screening Columns Stationary Phase Column ph Range a Manufacturer Part Number C18 Twin Technology Gemini C18, 5 m, 110A, 4.6 x 150 mm 1-12 Phenomenex 00F-4435-E0 Phenyl with Hexyl (C6) linker, Luna Phenyl-Hexyl, 3 m, 4.6 x 150 mm Phenomenex 00F-4256-E0 endcapped C18-20% C loading Discovery HS-C18, 3 m, 4.6 x 150 mm 2-8 Supelco U C18 polar embedded, hybrid particle with Shield Technology XTerra RP18, 3.5 m, 4.6 x 150 mm 1-12 Waters C18 silica Sunfire C18, 3.5 m, 4.6 x 150 mm 2-8 Waters Pentafluorophenyl Curosil PFP, 3 m, 4.6 x 150 mm Phenomenex 00F-4122-E0 a Columns were screened only against mobiles phases within their compatible ph range.
35 HPLC Screening Conditions: An Example Orthogonal Screening Method Description Time (min) %Water %Acetonitrile % Modifier a Flow Rate (ml/min) Injection Volume 5 L Detection 280 nm; DAD ( nm) Column Temperature Ambient Sample Temperature 5 o C a Modifier stock solutions are prepared at a concentration 20 times higher than the desired mobile phase concentration since mobile phases are prepared at time of use with the HPLC quaternary pump. Modifier Mobile Phase Approximate ph Concentration Trifluoroacetic Acid (TFA) 0.05% 2 Formic Acid 0.1% 2.8 Ammonium Acetate + Acetic Acid 8 mm + 0.1% 4 Ammonium Acetate 8 mm 7 Ammonium Acetate + Ammonium 8 mm % 10.2 Hydroxide Ammonium Hydroxide 0.05% 10.8
36 Method Optimization Examples of optimization parameters: Organic modifier Gradient slope ph Buffer (type, concentration) Flow rate Colum temperature Gel lots of column Sample solvent Injection volume Typically monitored characteristics: Retention time Resolution Tailing factor General approaches: One factor at a time Design of experiments (DOE)
37 Example of Primary and Secondary Method mau Active HPLC method YMC Pro C18 ph mau Orthogonal HPLC method XTerra RP 18 C18 ph 7 min min Ref. H. Rasmussen et al, HPLC method development, in S. Ahuja and M.W. Dong, ed, 37Handbook of Pharmaceutical Analysis by HPLC, Elsevier, Amsterdam, 2005, Chapter 6.
38 Approaches to Maximize Method Orthogonality Separation mode Reversed phase (RP) o o Different stationary phase Buffer/pH Normal phase (RP) Hydrophilic interaction Chromatography (HILIC) Detection Different UV wavelength Mass spectrometry Charged aerosol detector (CAD)
39 AU D Case #1. Complementary Selectivity of Different Separation Modes: Reversed Phase at -Low PH A B C Minutes Col: 250 3mm 5 m Nucleosil Protect-1; MPA: 0.3% H 3 PO 4 ; MPB: MeCN; Gradient: Time(min) MPA(%) MPB(%) Flow-rate: 0.3 ml/min; Column temp: 40 C
40 Case #1. Reversed Phase at High ph Col: mm 5 m Gemini C18; MPA: 0.3% Triethylamine; MPB: MeOH; Gradient: Time(min) MPA(%) MPB(%) Flow-rate: 1.0 ml/min; Column temp: 40 C
41 Case #1. Normal Phase Col: mm 5 m YMC- Pack SIL; MPA: EtOH; MPB: Hexane; Gradient: Time(min) MPA(%) MPB(%) Flow-rate: 1.5 ml/min; Column temp: 30 C
42 Case #1. Hydrophilic Interaction Chromatography (HILIC) Col: mm 5 m YMC-Pack DIOL; MP: 94/6, MeCN/50mM NH4OAc; Flow-rate: 1.5 ml/min; Column temp: 30 C
43 Case #1. Complementary Selectivity of Different Separation Modes Method Elution Order Observations Run time (min) Reversed phase Low ph A, B, C, D Difficult to resolve A & B on most columns 55 Reversed phase High ph B, C, A, D Limited selection of columns at ph ~12 Higher risk of interference Normal Phase D, A, B, C Low peak efficiency Challenging sample preparation HILIC D, B, A, C Short run time, better peak shape and efficiency
44 Case #2. Complementary Selectivity of Different Separation Modes (RP vs. HILIC) Compd Functional Groups 1 Aromatic, -NH 2, -OH 2(API) Aromatic, -NH 2, -O-CONH 2 3 Aromatic, -OH, -NH-CONH 2 4 Aromatic, -O-CONH- Ref: X. Wang, W. Li, H. Rasmussen, J. Chromatogr. A, 1083 (2005), 58.
45 Case# 2: HILIC Method Validation Summary Category Specificity Accuracy Limit of Quantitation Linearity Precision Results All peaks of interest are separated. The peaks are free of co-elution as demonstrated by RP-HPLC orthogonal method and peak purity analysis on the UV spectra. The recovery from multiple sample preparation is within the range of 99.2% to 100.6% ng; or 0.05% of standard concentration (0.75mg/mL, 10 L injection, S/N =10) In the range of 0.05% to 120% of standard concentration (0.75mg/mL), the curve composed of 7 data points is linear (R 2 =0.9999). 5 injections of the same standard solution (0.75mg/mL) have a relative standard deviation of 0.4%; 3 individual sample preparations at different concentration levels have a relative standard deviation of 0.8%. 45
46 Summary of Phase Appropriate Method Development Systematic method development process Stressed sample Method screen Primary/secondary method Method optimization Method validation Approaches to enhance method orthogonality Separation mechanism (HILIC vs. RS for R331333) Detection (UV vs. CAD for paclitaxel and gentamicin/proclin) Phase appropriate development and validation Build up knowledge base for DS/DP in early phase Establish robustness (define design space) in late phase
47 Triggers of Post-market Method Changes New submission (renewal) to worldwide markets Compendial updates New Guidelines Development of new formulations (combination products) / new API synthetic route Change of manufacturing process Change of source/chemistry of raw materials/intermediates Method transfer to different sites New analytical techniques/improved methods Inspections Events/Observations: stability monitoring; complaints; counterfeits Periodic review/monitor
48 Analytical Method Transfer Types of method transfer: Comparative testing Co-validation between two laboratories Method validation/re-validation Transfer waiver Steps towards successful method transfer: Discussions initiated Method and validation reviewed Laboratory evaluated Transfer protocol written and approved Experimental data generated Transfer report written and approved
49 Method Change Triggered by Periodic Monitor/ Review of Methods in Testing Labs Is the method inadequate by today s scientific standard or regulatory requirement? Is sufficient data available to permit simplification of the method? Does monitoring of laboratory deviation suggest a need for method improvement? Do newer method for similar products significantly outperform? Is the volume of testing justify further method optimization or automation?
50 Life Cycle of Post-approval Analytical Methods Assessment Id gap Open Change Control Method development Report to authority Transfer Validation Implementation Close change control Periodic review monitoring
51 Change Control Process Flow Pre-CoC meeting Open CoC Site/funtional assessment Authority approval QA/Board approval Site/functional approval Site/functional Implementation Close change control
52 Change Control Request for change Change control No. Date Type/category of change Change related to product/document/system/facility Concerned documents with number Description of change Reason for change Impact of change Assessment of Impacted sites/functions Proposed methodology for Implementation Closure
53 Why Is Change Control Critical? Compliance risks due to no/ineffective change control o o o o o o o o o o o Method not aligned with Local regulatory filing Local regulatory filing not consistent with global regulatory filing Global regulatory filing not consistent with latest version of methods Translation to local language is not accurate Wrong version of test method is used at different sites Methods not validated Method not validated according to today s standard Missing information Calculation error Inappropriate system suitability Compendial changes in each country Effective change control system provides evidence of compliance to FDA. It is invaluable to maintain a history of the lifecycle of all change requests.
54 Summary Analytical methods are essential part of product life cycle Method development/validation activities should be phase appropriate: IND, NDA, post approval New FDA guideline on analytical methods reflects current thinking of agencies and industry trend: to proactively address method issues Robust method development is the best investment in life cycle of analytical methods It is important to manage post-market changes to analytical methods
Analytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationBivalirudin Purification:
Bivalirudin Purification: Sorbent Screening and Overload Experiments Marc Jacob, Joshua Heng, and Tivadar Farkas Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA PO94190412_W Abstract In this
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationHPLC to UPLC Method Migration: An Overview of Key Considerations and Available Tools
HPLC to UPLC Method Migration: An Overview of Key Considerations and Available Tools Dr. Michael Swartz, Ph. D. Principal Consulting Scientist Worldwide Pharmaceutical Business Operations Waters Corporation
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationQuality-by-Design-Based Method Development Using an Agilent 1290 Infinity II LC
Quality-by-Design-Based Method Development Using an Agilent 129 Infinity II LC An Efficient Method Development Workflow Combined with ISET-mediated Method Transfer Under Waters Empower 3 CDS Control Application
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationDeveloping and Validating Dissolution Procedures for Improved Product Quality
W H I T E P A P E R Developing and Validating Dissolution Procedures for Improved Product Quality By Michael Swartz, Ph. D., Director of Research and Development, and Mark Emanuele, Chemist Abstract In
More information11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS. Siriphorn Laomanacharoen 21 December 2012
11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Siriphorn Laomanacharoen 21 December 2012 11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Organised by European Directorate
More informationAnalysis and Purification of Polypeptides by Reversed-Phase HPLC
Analysis and Purification of Polypeptides by Reversed-Phase HPLC Reversed-phase HPLC is a valuable tool for the analysis and purification of proteins and peptides. It is effective in separating peptide
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationPromix TM. Enter a New Era in Biomolecule Analysis with. Columns. Unsurpassed Selectivity and Peak Capacity for Peptides and Proteins
Promix TM Enter a New Era in Biomolecule Analysis with Promix TM Columns Unsurpassed electivity and Peak Capacity for Peptides and Proteins Applications: Proteomics Peptide/Protein Analysis Peptide/Protein
More informationSize Exclusion Chromatography of Biosimilar and Innovator Insulin Using the Agilent AdvanceBio SEC column
Size Exclusion Chromatography of Biosimilar and Innovator Insulin Using the Agilent AdvanceBio SEC column Application Note Bio-Pharmaceutical Authors M. Sundaram Palaniswamy and Andrew Coffey Agilent Technologies,
More informationADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS
Agilent AdvanceBio Columns ADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS with Agilent ZORBAX RRHD 3Å 1.8 µm columns ns Rapid resolution high definition columns for UHPLC protein and peptide separations
More informationGenotoxicity is the property of a compound
Impurities Analysis in Pharmaceuticals: Genotoxicity is the property of a compound known to have irreversible effects on the structure and functionality of the DNA in cells and cause DNA loss, DNA replication
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationFast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides
Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides High-pH-stable, superficially porous particle columns for LC/UV and LC/MS Application Note Biologics and Biosimilars Authors
More informationQuantification of Drug Metabolites in Early-Stage Drug Discovery Testing
Quantification of Drug Metabolites in Early-Stage Drug Discovery Testing Christopher Crafts, Bruce Bailey, John Waraska, Ian Acworth Thermo Fisher Scientific, Chelmsford, MA, USA Overview Purpose: The
More informationPeptide Mapping: A Quality by Design (QbD) Approach
Peptide Mapping: A Quality by Design (QbD) Approach Application Note Bio-Pharmaceutical Authors Sreelakshmy Menon and Suresh babu C.V. Agilent Technologies, Inc. Richard Verseput S-Matrix Corporation Abstract
More informationAdvanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming
Advanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming Dr. Jörg Hoffmann / Global Drug Product Governance and CMC Compliance, Merck KGaA (EMD Serono in US) IFPAC Annual Meeting,
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationOverview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only
More informationImproving Resolution and Column Loading Systematically in Preparative Liquid Chromatography for Isolating a Minor Component from Peppermint Extract
Improving Resolution and Column Loading Systematically in Preparative Liquid Chromatography for Isolating a Minor Component from Peppermint Extract Jo-Ann M. Jablonski and Rui Chen Waters Corporation,
More informationNew Core-Shell Technology
New Core-Shell Technology Fortis Speedcore columns are the very latest in core-shell technology. Incorporating our optimised bonding and packing practices with a core-shell particle provides the analyst
More informationStarting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationZwitterion Chromatography ZIC
Zwitterion Chromatography ZIC A novel technique, with unique selectivity, suitable for preparative scale separations? PhD Einar Pontén What is Zwitterion Chromatography? Our definition: Liquid chromatography
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationGUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)
GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) DRAFT GUIDANCE This guidance document is for feedback purposes only Comments and suggestions regarding this draft document should be submitted within
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationMartin Gilar Waters Corporation, Milford, MA, U.S. Origins of synthetic oligonucleotides impurities. Lab-scale isolation options
LIGNUCLETIDE SEPARATIN TECHNLGY: SYNTHESIS CHALLENGES AND HPLC ISLATIN PTINS Martin Gilar Waters Corporation, Milford, MA, U.S. INTRDUCTIN rigins of synthetic oligonucleotides impurities Use of synthetic
More informationAccucore. Ultimate Core Performance LC Column Technology to Maximize Your Investment. Dave Jarzinski. October 2011
Accucore Ultimate Core Performance LC Column Technology to Maximize Your Investment Dave Jarzinski Thermo Fisher Scientific Account Manager Greater Boston/Cambridge & North Phone: 978-408-1576 Email: dave.jarzinski@thermofisher.com
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More information7 Preparative Columns
YMC GENERAL CATALOG Overview of optimization methods for isolation/purification YMC-Actus series YMC-Pack Pro C18 YMC-Pack R&D series YMC-Pack preparative columns ODS series C8 C4 TMS Ph CN SIL SIL-06
More informationHIC as a Complementary, Confirmatory Tool to SEC for the Analysis of mab Aggregates
HIC as a Complementary, Confirmatory Tool to SEC for the Analysis of mab Aggregates Julia Baek, Shanhua Lin, Xiaodong Liu, Thermo Fisher Scientific, Sunnyvale, CA Application Note 2126 Key Words Size exclusion
More informationBÜCHI Labortechnik AG
BÜCHI Labortechnik AG Purification BUCHI Chromatography History 1977: BUCHI Fraction Collector 1978: 1 st preparative chromatography system 2008: automated chromatography system 2014: automated high performance
More informationValidated Stability-indicating assay method for determination of Ilaprazole in bulk drug and tablets by high performance liquid chromatography
Validated Stability-indicating assay method for determination of Ilaprazole in bulk drug and tablets by high performance liquid chromatography Pradeep G. Shelke a*, Anil V. Chandewar a, Anil P. Dewani
More informationOptimizing the Purification of a Standard Chiral Compound Utilizing a Benchtop, Multi-Purpose, Semi-Preparative to Preparative HPLC System
Optimizing the Purification of a Chiral Compound Utilizing a Benchtop, Multi-Purpose, Semi-Preparative to Preparative HPLC System Application Note PHA0111 Keywords Chiral, Enantiomer, HPLC, Normal Phase
More informationVerification of Compendial Methods
Verification of Compendial Methods ภญ.ดร ดร.ส ภาณ ดวงธ รปร ชา ส าน กยาและว ตถ เสพต ด กรมว ทยาศาสตร การแพทย 7 ม ถ นายน 2556 1 Scopes : Overview Asean Analytical Validation Guidelines Verification of Compendial
More informationA Modular Preparative HPLC System for the Isolation of Puerarin from Kudzu Root Extracts
A Modular Preparative HPLC System for the Isolation of Puerarin from Kudzu Root Extracts Andrew Aubin and Ronan Cleary Waters Corporation, Milford, MA, USA APPLICATIN BENEFITS A modular preparative HPLC
More informationMethod Translation in Liquid Chromatography
Method Translation in Liquid Chromatography Technical Overview Abstract Ronald E. Majors Agilent Technologies, Inc. 2850 Centerville Rd Wilmington, DE 19808 USA With the recent emphasis on high performance
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationForced Degradation of Ibuprofen in Bulk Drug and Tablets
Forced Degradation of Ibuprofen in Bulk Drug and Tablets and Deteration of Specificity, Selectivity, and the Stability-Indicating Nature of the USP Ibuprofen Assay Method Sherri Farmer, Pamela Anderson,
More informationCombining High Temperature and Small Particles: The Advantages of Zirconia
Combining High Temperature and Small Particles: The Advantages of Zirconia EAS 9 Dan owlan 1, Bingwen Yan 1, Clayton V. Mceff 1, R.A. Henry 1 ZirChrom Separations, Inc. 617 Pierce St., Anoka, M 5533 Independent
More informationQuality by Design (QbD) Based Development of a Stability Indicating HPLC Method for Drug and Impurities
Quality by Design (QbD) Based Development of a Stability Indicating HPLC Method for Drug and Impurities S. Karmarkar*, R. Garber, Y. Genchanok, S. George, X. Yang, and R. Hammond Baxter Healthcare Corporation,
More informationQualification of High-Performance Liquid Chromatography Systems
Qualification of High-Performance Liquid Chromatography Systems L. Huber Hewlett- Packard GmbH, Waldbronn December 1998 Manuscript of an article published in BioPharm, Vol 11 Number 11, November 1998,
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationmabs and ADCs analysis by RP
mabs and ADCs analysis by RP Shanhua Lin, Ph.D. The world leader in serving science Protein and mab Separation by HPLC Size difference? YES Size Exclusion Chromatography (SEC) MAbPac SEC-1 NO NO Charge
More informationBioanalytical method validation: An updated review
Review Article www.phmethods.org Bioanalytical method validation: An updated review Abstract The development of sound bioanalytical method(s) is of paramount importance during the process of drug discovery
More informationOverview of preparative HPLC. Analytical Technologies Limited
Overview of preparative HPLC Analytical Technologies Limited 1.Review of liquid phase chromatography origin develop prospect Mobile phase Tewett 1903 Stationa ry phase origin Separation result Liquid-stationary
More informationCertificate of Analysis
Certificate of Analysis ISO GUIDE 34 ANAB Cert# AR-1470 ISO/IEC 17025 ANAB Cert# AT-1467 SORBITOL CERTIFIED REFERENCE MATERIAL CERTIFIED PURITY: 98.4 %, U crm = ±0.1 % k = 2 (Mass Balance/as is basis)
More informationFundamentals and Techniques of Preparative HPLC. Parto Zist Behboud Tel: 42108
Fundamentals and Techniques of Preparative HPLC Parto Zist Behboud www.partoz.com Tel: 42108 Today s Overview 1 Basic know-how for up-scaling 2 Practical examples of up-scaling 3 Recycle preparation 4
More informationInternational Journal of Generic Drugs
Photostability STABILITY TESTING in New Drug Products evaluating photostability is foremost for new chemical entities only - not in generic drugs, provided the container-closure protection is the same
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More informationPharma EXPO 6 9 November 2016 Chicago, IL
DESIGN TO VALUE: An End-to-end Lifecycle Methodology, Enabling Customer-centric, High-quality Products, Made Efficiently and Reliably Susan Neadle Senior Director Design to Value & Product Quality Management
More informationMethod Development Considerations for Reversed-Phase Protein Separations
Method Development Considerations for Reversed-Phase Protein Separations Hillary B. Hewitson, Thomas E. Wheat, Paula Hong, Kenneth J. Fountain APPLICATION BENEFITS n The BEH00 C 4 chemistry is available
More informationCertificate of Analysis
Certificate of Analysis IS GUIDE 34 ANAB Cert# AR-1470 IS/IEC 17025 ANAB Cert# AT-1467 CLARITHRMYCIN CERTIFIED REFERENCE MATERIAL H 3 C H H 3 C H 3 C H H N H CERTIFIED PURITY: 97.3%, U crm = ±0.9% k =
More informationCertified Reference Material - Certificate of Analysis
Certified Reference Material - Certificate of Analysis S(-)-Nicotine, Primary Standard N-008 Page 1 of 7 Catalog Number: N-008 H Lot: Expiration: October 2019 N Description: S(-)-Nicotine in Methanol.
More informationChem 321 Lecture 23 - Liquid Chromatography 11/19/13
Chem 321 Lecture 23 - Liquid Chromatography 11/19/13 Student Learning Objectives High Performance Liquid Chromatography With the advent of relatively inexpensive and reliable pumps, the development of
More informationFast Preparative Column Liquid Chromatography (PCLC)
Fast Preparative Column Liquid Chromatography (PCLC) Application Note 224 Joan Stevens, Ph.D. and Gary Scharrer Introduction Preparative HPLC is recognized as a prime method for obtaining pure compounds
More informationGuideline on the chemistry of active substances for veterinary medicinal products
9 November 2017 EMA/CVMP/QWP/707366/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the chemistry of active substances for veterinary medicinal products Draft agreed by Quality
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationPharmacopoeial Reference Standards
Pharmacopoeial Reference Standards Industry view point Antony Raj Gomes Head- Quality Management 1 Presentation Overview Indian Industry an update Available guidelines Industry practices Current challenges
More informationIMPURITIES. Antony Fake API Focal Point, PQTm WHO PREQUALIFICATION TEAM MEDICINES
IMPURITIES Antony Fake API Focal Point, PQTm IMPURITIES PQTm Training Copenhagen, May 2016 1 Introduction This presentation is made with reference to the preparation of an API. This is because the API
More informationCurrent Features of USFDA and EMA Process Validation Guidance
Human Journals Review Article April 2016 Vol.:6, Issue:1 All rights are reserved by Patwekar S.L et al. Current Features of USFDA and EMA Process Validation Guidance Keywords: Pharmaceutical validation,
More informationTechnical Overview. Author. Abstract. Edgar Naegele Agilent Technologies, Inc. Waldbronn, Germany
New Features of the Agilent Method Scouting Wizard for Automated Method Development of Complex Samples Analysis of Large Data Sets by Method Scouting Reports and Automated Adjustment of Flow Rates and
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationAntibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products
Antibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products Fred Jacobson Protein Analytical Chemistry Genentech, Inc. CASSS CMC Strategy Forum Japan 2013 December 9-10,
More informationMaximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns
Maximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns Hongwei Xie, Martin Gilar, and Jeff Mazzeo Waters Corporation, Milford, MA U.S. APPLICATION BENEFITS The ACQUITY UPLC
More informationMethod Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology
Technical Overview Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Introduction Online fiber-optic and multicell UV-dissolution systems have become increasingly
More informationUpdate to USP <621> Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014
Update to USP Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014 2015 Waters Corporation 1 What is the USP-NF? The United States Pharmacopeia National Formulary (USP-NF)
More informationTEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES
VICH GL39 (QUALITY) November 2005 For implementation at Step 7 TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES Recommended for
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationHPLC/FLASH Purification ADVANCE THE PACE OF YOUR DISCOVERY TO ACHIEVE THE RESULTS OF TOMORROW
HPLC/FLASH Purification ADVANCE THE PACE OF YOUR DISCOVERY TO ACHIEVE THE RESULTS OF TOMORROW PLC Purification Systems Accelerate the pace of your discovery S ave time by minimizing the number of fractions
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationEvaluation of rice husk as an excipient for the pharmaceutical industry
Evaluation of rice husk as an excipient for the pharmaceutical industry Fernández_Ledesma E. 1, Rodríguez _Acosta C. 1, Liva_Garrido M. 2, Díaz_ Polanco I. 3, Cazanave_Guarnaluce D. 3 1 Engineering and
More informationImproved SPE for UPLC/MS Determination of Diquat and Paraquat in Environmental
Improved SPE for UPLC/MS Determination of Diquat and Paraquat in Environmental Samples Michael S.Young, Jeremy C. Shia, Kim vantran, Kevin M. Jenkins and Masayo Yabo Waters Corporation 34 Maple Street,
More informationFast mass transfer Fast separations High throughput and improved productivity Long column lifetime Outstanding reproducibility Low carryover
columns ProSwift Reversed-Phase Monolith Columns for Protein Analysis ProSwift reversed-phase columns use a unique monolith technology for fast, high-resolution HPLC and LC/MS separations of proteins.
More informationHPLC METHODOLOGY MANUAL
HPLC METHODOLOGY MANUAL DISTRIBUTED PHARMACEUTICAL ANALYSIS LABORATORY (DPAL) Revision Date 2016-08-04 Professor Marya Lieberman Department of Chemistry and Biochemistry University of Notre Dame Notre
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationPreparative, Pilot & Process Columns
Preparative, Pilot & Process Columns 321 Preparative, Pilot & Process Columns Contents Prep Columns... 322-323 Dynamic Axial Compression Columns (DAC)... 324-325 Pilot Columns... 326-327 Chromatography
More informationACQUITY UPC 2 BEH, CSH, and HSS Columns
ACQUITY UPC 2 BEH, CSH, and HSS Columns CONTENTS I. INTRODUCTION II. GETTING STARTED a. Safety Considerations b. Column Connectors and Installation c. ecord Installation d. Column Equilibration e. Initial
More informationConcentration of Human Hormones in Drinking Water Using Solid Phase Extraction and Analysis by High Performance Liquid Chromatography
Concentration of Human Hormones in Drinking Water Using Solid Phase Extraction and Analysis by High Performance Liquid Chromatography Carl Fisher, Monika Verma, and Pranathi Perati; Thermo Fisher Scientific,
More informationFurther Stability Considerations
Further Stability Considerations Radhika Rajagopalan, Ph.D., Team Leader Chemistry Division 2 Office of Generic Drugs, FDA FDA-GPhA Workshop June 4, 2013 1 Agenda Common considerations Q1D Bracketing and
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationLC/MS. Why is it the fastest growing analytical technique?
LC/MS Why is it the fastest growing analytical technique? Discussion topics Evolution of LC/MS Advantages of API Why should I use LC/MS? LC/MS markets Evolution of LC/MS interfaces 1970s to Present Moving
More informationSFC Säulen für analytische und preparative Anwendungen
SFC Säulen für analytische und preparative Anwendungen Technology Symposium Vienna, 25 th October 2016 DI Verena Schmid 2016 Waters Corporation 1 CHIRAL SEPARATIONS ACQUITY UPC 2 Trefoil 2016 Waters Corporation
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationCurrent FDA Perspective for Continuous Manufacturing
Current FDA Perspective for Continuous Manufacturing Sau (Larry) Lee, Ph.D. Deputy Director (Acting) & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US
More informationZORBAX StableBond HPLC Columns
ZORBAX HPLC Columns Longest column lifetime and best reproducibility for low ph separations down to ph 1 Patented stable column chemistry allows use at high temperature and low ph without degradation Six
More informationLeachable and Extractable Testing
Leachable and Extractable Testing A Primer on Regulations and Methods As presented to By: Anthony Grilli, MS General Manager SGS LSS NJ Laboratory 973 244 2435 Anthony.Grilli@SGS.com Summary Why perform
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More information